Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
When people panic, it really works out well for those of us who don't. If people panic at this level of volatility then they need to pull up the charts for just about any other emerging biotech out there - we have it pretty easy over here at CTIX.
Just got me some 2.97
Thanks for putting this back up. How do we get offending moderators removed?
Yes, and since history has proceeded to repeat itself and there is every indication it will repeat itself again with a major upside breakout, there is really only one decision to make - how much can one afford to buy?
On a better tangent - these prices seem kind of nice to get shares before NASDAQ. Not sure if there is a better guaranteed 100% gain than with CTIX.
When your tactics don't work - try quoting the TOS agreement/rules while attaching the name of someone deeply respected to the post. When this doesn't work maybe try telling Mommy.
Analyst target of $40, I'd be OK with that after all these years...
Haha - No kidding! What are we supposed to compare with? It only has taken the S&P 500 about 72 months to triple - and that at its quickest rate (1995 thru 2000 and the current triple 2009 thru 2015). Even with all the stagnation CTIX has been fantastic and sees less volatility than its peers.
One final period of downward pressure preceeds most rallies... is this our signalling precursor? I'm ready.
Yep, I guess it's all relative... I also expect Q1 to be a great improvement over Q4, and that right there is why the $25 price targets are more appropriate than the analysts' targets near this current pps. Q over Q growth has been proven over several quarters to be great and there is no reason to think that is going to do anything but maintain or even improve with cytosorbents ever expanding product channels and success stories.
Just a couple weeks till sales numbers that blow peoples' minds come out... me thinks.
To offset my not selling some yesterday I bought some just now. I figure it should pay off just as well if not much more! My quick review of their latest filing looked like plenty of cash for several months of operations.
Ha - I must laugh at this! You just said "no worries man" to gov. She is like the Wisewoman of our CTIX tribe. "no worries man" haha The price moves today definitely help keep the board on the lighter side - Go CTIX!
Right, so are we to assume that Cellceutix has already formulated some additional Kevetrin-like compounds and delivered them to MD Anderson? I would love to hear that Kevetrin is now considered an entire platform of compounds and that MD Anderson has determined a method for perfecting each compound to act against its chosen cancer.
The Biotech sector rewards single drugs heavily and applies plenty of focus on single drug development companies. Will Cellceutix usher in a whole new paradigm centered on total platform development that dwarfs prior valuations?
My guess is that the largest patient population at the highest dose will begin to reveal more cancers that Kevetrin works best against and will therefore inform MD Anderson about which cancer cell lines to spend their time and money researching. I am guessing they already know a few to try out (e.g. ovarian), but the further the phase I, the more informed MD Anderson's preclinical search becomes.
Those could be some fantastic PR's: "MD Anderson indentifies X number of cancer cell lines that show strong apoptosis responses to Kevetrin"
p.s. I would also like to know why 'drugs' is plural. Kevetrin and some additional formulation(s)?
Haha - not trying to cast sunshine into your dungeon, but nobody mentioned this valuation going into effect tomorrow.
I would also be OK with that number! However, if Kevetrin works on not only 4 types of blood cancer as PCYC's drug, but rather blood and half of all solid tumors, and Brilacidin kills most superbugs, and an entire definsin mimetic platform becomes validated, and antiinflammatory aspects are realized, pluc antifungals, plus IB/crohns, then the $800 I mention below enters the field of view. Damn the next several months are going to be exciting!
That would be about $200 pps
Here is my hypothesis (if it has been discussed then my bad, don't want to read through the BS): our management recently met with Dr. Reddy's about the formulation progress with Brilacidin and relating defensin mimetic compounds. They have formulated not only a temp stable form for diabetic ulcers, but have also developed an oral form that has informed our management to expand our defensin platform into skin diseases wherein patients prefer oral form medication due to often dosing requirements such as acne and it's derivatives. Pharmacodynamic information from the recent trial may have also informed this product expansion. Soon Leo will announce a partnership/agreement with Dr. Reddy's with an upfront multi-million dollar payment to secure Dr. Reddy's as the sole producer of Brilacidin or perhaps a different related definsin mimetic compound. Ha, not sure, the hypothesis jumped into my mind after I read the PR this morning. Go CTIX!
Of course, if I were in charge of the committee that determined inclusion and Cellceutix wanted in, I'd just waive any requirements and let the company of a lifetime join before a competing index got them... but I am biased!
Sure, but many topics, including making payments to employees for work performed and making interest payments on loans for operating expenses also qualify as operating activities. Revenue generating operations is just another form of operating activities, there are several. I guess the point is, NASDAQ may just consider CTIX having met the operating history guideline. I'm guessing we find out sooner rather than later if they qualify for NASDAQ, I'm also guessing we will never know for what specific reasons that NASDAQ considered them qualified.
I also am unable to make any link between 'operating activities' and 'cash flow' wherein that cash flow is required to be positive to establish history. CTIX has had operating activities ongoing for several years, definitely the 3+ that I have been invested.
So CTIX now has a Director of Chemistry, Siya Ram?
https://www.linkedin.com/pub/siya-ram/89/616/413
How new is this? Interesting - no doubt Dr. Ram is extremely qualified.
Education
Central Drug Research Institute, Indai
Doctor of Philosophy (Ph.D.), Medicinal and Pharmaceutical Chemistry
I agree. I also won't be surprised if those figures are low. As efficacy is demonstrated the product will proliferate via medically beneficial product demand that was non-existent in the prior 50+% Q over Q sales growth quarters.
And it won't be the last! This little filter is going to be huge glad I loaded up on CTSO more and more as these reports come out. No doubt these doctors that have these experiences make sure their cytosorb supply cabinet is stocked with product. Looking forward to the next quarterly filing, short weeks away...
CTIX Investor Party attire update:
(1) Rally Monkey T-shirt
(2) Hat of your favorite meat
LOL
Ooo - interesting close. eom
Major bummer man! Oh well, perhaps we do owe our country's forefathers a holiday - they did foster the creation of this beautiful capitalistic nation where I can participate in the success of Cellceutix.
Edit: hehe Go CTIX!
Going on 3 weeks since last PR - looking forward to Monday!
And I do believe that CTIX's uplist is going to be even more explosive than CT**'s. Way more market potential behind this one, their institutional inrush will pale in comparison - it's going to be fun to participate!
Perhaps we are lucky that most cannot read between the lines, otherwise it would have been much more costly to build our positions.
Some people have not figured out Leo's style. He uses the term momentous and the stock more than doubles hitting almost $5 within a month. Leo mentions recent events suggesting a meeting with legal about uplisting... Well, some of us are fortunate to have figured out his style. It's ok, maybe by $50 or $100 the rest will figure it out also.
Haha - well Leo sure opened up his can of whoopass and sprayed 'em down good this week
Yep, get used to frequent new all time highs!
I propose rally monkey t-shirts for investor party attire! Someone must have a screen print hookup.
Leo and team's devotion to their shareholders is astounding, not to mention the devotion to the science. I've had my money here for going on 4 years, no better place for it, support for us during times when the market is irrational - very comforting to my account balances.
I think too many people overestimate the necessity of FDA approval. I'm not saying it's not the ultimate ideal, but it kept people timid about buying in early with CTSO. I'm the same way, find a good biotech and hold for massive gains. Seeing CTSO take an alternate path straight to revenue through EU approval before tackling the FDA was a thumbs up in my book and my money followed and my portfolio benefitted. Great story here.
I actually did a CT** ticker search to see what else I was missing out on - my two biggest winners by far, 200+% portfolio gainers in a couple years, both CT**.
CT**'ers unite! It's almost a club, haha